Scarica l'app Stockscreener
4.48
3.33%
0.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Arbutus Biopharma Corp Borsa (ABUS) Ultime notizie
Arbutus Posts Profit After Moderna Patent Settlement - MyChesCo
ABUS Stock Price, Quote & Chart | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake - Stock Titan
Arbutus Biopharma Corp Q1 2026 Financial Results and Business Update – Clinical Progress in Hepatitis B Therapies - Minichart
Arbutus Biopharma Corporation 8-K Filing: Company Details, Financial Data, and NASDAQ Listing (May 2026) - Minichart
Is Arbutus Biopharma (ABUS) Overvalued After Q1 2026 Earnings Be - GuruFocus
Arbutus Biopharma (ABUS) Reports Strong Q1 Earnings with $0.87 E - GuruFocus
Arbutus Biopharma Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Arbutus Biopharma earnings beat by $0.91, revenue topped estimates - Investing.com
Arbutus Biopharma Corp 1Q 2026: Revenue $179.13M, EPS $0.87— 10-Q Summary - TradingView
Arbutus: Q1 Earnings Snapshot - 10TV
Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit - Stock Titan
Arbutus (NASDAQ: ABUS) swings to Q1 profit on $179M revenue surge - Stock Titan
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - Stock Titan
Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS) - Seeking Alpha
MSN Money - MSN
Arbutus Biopharma Corporation (ABUS) Stock Analysis: Exploring a 20% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Arbutus Biopharma (ABUS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
5 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
Whitefort lifts Arbutus (ABUS) economic stake to 9.8% - Stock Titan
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran - Insider Monkey
Arbutus Drug Candidate Receives FDA Fast Track Designation - MyChesCo
ABUS (Arbutus Biopharma) Other Liabilities for Banks - GuruFocus
FDA grants Arbutus Biopharma drug fast track designation - Pennsylvania Business Report -
Arbutus (ABUS) Stock: Stability Assessment (Momentum Fading) 2026-04-20Trending Momentum Stocks - newser.com
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability - Insider Monkey
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Whitefort Capital Management, LP Increases Stake in Arbutus Biop - GuruFocus
Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Arbutus Biopharma (ABUS) Receives FDA Fast Track Designation for Imdusiran - GuruFocus
Arbutus Biopharma Corp ($ABUS) Former Interim President and CEO 2025 Pay Revealed - Quiver Quantitative
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseHere's Why - MarketBeat
Arbutus Biopharma Corporation Files Form 8-K with SEC – Company Details, Address, and NASDAQ Listing Information 24252675 - Minichart
ABUS Receives Fast Track Designation from FDA for Imdusiran - GuruFocus
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - The Manila Times
[8-K] Arbutus Biopharma Corp Reports Material Event - Stock Titan
Arbutus Biopharma (ABUS) 2026 proxy adds 16.3M-share incentive plan vote - Stock Titan
Whitefort outlines 8.1% Arbutus Biopharma (ABUS) stake in amended 13D - Stock Titan
ABUS Technical Analysis | Trend, Signals & Chart Patterns | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Arbutus reports results, announces $2.25B Moderna settlement - MSN
ABUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):